New targeted agent produces considerable responses in patients with uterine cancer
Friday, April 24, 2020 - 16:40
in Health & Medicine
The DNA repair-blocking drug adavosertib shrinks tumors in nearly one-third of patients in clinical trial data to be shared at the Society for Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer.